2012: A Good, Bad or Ugly Year for Servier? - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

2012: A Good, Bad or Ugly Year for Servier?
The scandal surrounding Servier's diabetes drug, Mediator, continues to unravel in France and could have implications for the whole pharmaceutical industry as the country scrutinises its regulatory systems.

Pharmaceutical Technology Europe
Volume 24, Issue 2


1. E. Lanez, "Mediator : l'effarante boîte à mensonges" (Le Point.fr, 2011) http://www.lepoint.fr, accessed Jan. 9, 2012.

2. B. Casassus, "With New Law, France Revamps Drug Approval" (Science, 2011). http://news.sciencemag.org/, accessed Jan. 9, 2012.

3. Servier, "Research is as vital as being an industry " (Servier website, 2011). http://www.servier.com/, accessed 9 Jan., 2012.

4. J. Upton, "Servier: patience and passion," Pharmaceutical Executive Europe (November 2008).

5. Focus Reports, "Interview—Jacques Servier" (2011). http://www.pharma.focusreports.net/, accessed 9 Jan., 2012.

6. K. Grogan, "Servier signs cancer deal with Sweden's BioInvent" (Pharma Times, 2012). http://www.pharmatimes.com/, accessed Jan. 9, 2012.

7. European Biotechnology Science & Industry News "Galapagos gets €4 million in alliance with Servier" (2011). http://www.eurobiotechnews.eu, accessed 9 Jan., 2012.

8. N. Jessop, Pharm. Technol. Eur. 23 (3), 14–18 (2011).

9. Le Point.fr, "Mediator, un jugement pour 2012?" (2011). http://www.lepoint.fr, accessed Jan. 9, 2012.

10. S. Sayare, "Scandal Over Mediator, a French Weight-Loss Drug, Prompts Calls for Wide Changes" (New York Times, 2011). http://www.nytimes.com/, accessed Jan. 9, 2012

11. Assemblée Nationale (2011). http://www.assemblee-nationale.fr/13/rap-info/i3552.asp, accessed Jan. 11, 2012

12. InPharm, "2011 Year In Review" (2012). http://www.inpharm.com/, accessed Jan. 9, 2012.

13. Le Nouvel Observateur, "Mediator: la cour rejette le regroupement des procédures" (2011). http://tempsreel.nouvelobs.com/, accessed Jan. 11, 2012.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology Europe,
Click here